2016

  • Ada H. V. Repetto-Llamazares, Roy H. Larsen, Adam O’Shea and Jostein Dahle
    Combination of 177Lu-Satetraxetan-Lilotomab and Rituximab Results in Improved Therapeutic Effect in Preclinical Models of Non-Hodgkin Lymphoma. Poster presented at 58th American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, CA, USA, December 3-6, 2016.
    Download PDF

  • Arne Kolstad, Ulf Madsbu, Matthew Beasley, Michael Bayne, Tim Illidge, Noelle O‘Rourke, Caroline Stokke, Tore Bach-Gansmo, Ayca Muftuler Løndalen, Jon Erik Holtedahl, Mona Elisabeth Revheim, Øyvind Bruland, Jostein Dahle, Laurie Baylor Curtis, Åse Østengen, Simon Turner, Nils Bolstad, Roy Hartvig Larsen, Signe Spetalen, Martin Erlanson, Stine Nygaard Rudå and Harald Holte Jr.
    177Lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL) Phase 1/2 Safety and Efficacy Data From Four Different Pre-dosing Regimens. Poster presented at 58th American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, CA, USA, December 3-6, 2016.
    Download PDF 
  • Arne Kolstad, Ulf Madsbu, Caroline Stokke, Tore Bach-Gansmo,  Ayca Muftuler Løndalen, Jon Erik Holtedahl, Mona Elisabeth Revheim, Øyvind Bruland, Jostein Dahle, Laurie Baylor Curtis, Åse Østengen, Helen Heyerdahl, Simon Turner, Nils Bolstad, Roy Hartvig Larsen, Signe Spetalen, Martin Erlanson, Stine Rudå Nygaard1 and Harald Holte Jr. 
    Pre-dosing with unlabelled antibody significantly increases the pharmacokinetic exposure and reduces haematological toxicity of 177Lu-lilotomab in non-Hodgkin B-cell lymphoma patients. Poster presented at EHA 2016, the 21st European Hematology Association Congress, in Copenhagen, Denmark, 9–12 June 2016.
    Download PDF 

  • Arne Kolstad, Ulf Madsbu, Matthew Beasley, Michael Bayne, Caroline Stokke, Tore Bach-Gansmo, Ayca Muftuler Løndalen, Jon Erik Holtedahl, Mona Elisabeth Revheim, Øyvind Bruland, Jostein Dahle, Laurie Baylor Curtis, Åse Østengen, Simon Turner, Nils Bolstad, Roy Hartvig Larsen, Signe Spetalen, Martin Erlanson, Stine Rudå Nygaard and Harald Holte Jr. 
    Efficacy and safety results of Betalutin® (177Lu-DOTA-HH1) in a phase 1/2 study of patients with non-Hodgkin B-Cell lymphoma (NHL). Poster presented AACR Annual Meeting 2016 in New Orleans, Louisiana, USA, 16 – 20 April 2016.
    Download PDF 

2015

  • Ada H. V. Repetto-Llamazares, Roy H. Larsen, Kirsti Solberg Landsverk, Trond Stokke, Bergthora Eiriksdottir, Roman Generalov and Jostein Dahle
    A treatment with 177Lu-HH1 increases CD20 expression in non-Hodgkin lymphoma cells in vitro and in vivo. Poster presented at 57th American Society of Hematology (ASH) Annual Meeting and Exposition, Orlando, Florida, USA, December 5-8, 2015.
    Download PDF 
  • J. Dahle, A. Repetto-Llamazares, K. B. Melhus, A. O’Shea, R. Generalov, J. T. Andersen, and H. Heyerdahl
    Comparison of murine and chimeric version of the anti-CD37 antibody HH1 used for antibody-radionuclide-conjugate (ARC) therapy of non-Hodgkin Lymphoma. Poster at the Annual Congress of the European Association of Nuclear Medicine (EANM), Hamburg, Germany, 10–14 October 2015.
    Download PDF 
  • A. Kolstad, U. Madsbu, J. Dahle, C. Stokke, T. Bach-Gansmo, A. M. Løndalen, J. E. Holtedahl, M. E. Revheim, Ø. Bruland, B. Bolstad, N. Bolstad, R. Larsen, S. Spetalen, S. R. Nygaard, M. Erlanson, H. Holte
    Results of a phase 1 study of 177Lu-DOTA-HH1 antibody radionuclide conjugate for patients with relapsed CD37+ non-Hodgkin lymphomas. Poster at ICML, Lugano Switzerland, June 2015.
    Download low-resolution PDF           Download high-resolution PDF
     
  • Helen Heyerdahl, Ada H. V. Repetto-Llamazares, Jostein Dahle
    Multiple Injections of Antibody-Radionuclide-Conjugates Targeting CD37 Increase Tolerability in Nude Mice bearing Non-Hodgkin Lymphoma Xenografts. Poster at EHA, Vienna, Austria, June 2015
    Download PDF 

2014

  • A. Kolstad, U. Madsbu, J. Dahle, C. Stokke, T. Bach-Gansmo, A. Muftuler Løndalen, J.E. Holtedahl, M.E. Revheim, Ø. Bruland, B. Bolstad, N. Bolstad, A. Tierens, R.H. Larsen, J.A. Alfheim, J. Delabie, S. Spetalen, M. Erlanson, S. Nygaard Rudå, H. Holte
    A phase I Study of 177Lu-DOTA-HH1 (Betalutin™) Radioimmunotherapy in Patients with Relapsed CD37+ Non-Hodgkin B-CellLymphoma. Poster at 56th ASH Annual Meeting and Exposition. San Francisco, CA, USA. December 2014.
    Download PDF 
  • H. Heyerdahl, A. Repetto-Llamazares, R.H. Larsen, B. Melhus, J. Dahle
    Multiple injection radioimmunotherapy by 177Lu-tetraxetan-HH1 reduce toxicity in nude mice. Poster at Annual Congress of the European Association of Nuclear Medicine (EANM), Gothenburg, Sweden, October 2014
    Dowload PDF
     


2012

  • A. Repetto-Llamazares, C. Mollatt, R. Larsen, A. Giusti, E. Riccardi, J. Dahle
    Long term toxicity studies of 177Lu-tetraxetan-tetulomab in nude mice. Poster at Annual Society of Nuclear Medicine and Molecular Imaging Meeting 2012 in Vancouver, Canada.
    Download PDF 


2011

  • J. Dahle, A. Repetto-Llamazares, C. Mollatt, K. Melhus, O. Bruland, A. Kolstad, R. H. Larsen
    Re-evaluation of CD37 as target for radioimmunotherapy of Non-Hodgkin Lymphoma. Poster at American Society of Hematology Annual Meeting 2011 in San Diego, USA.
    Download PDF 

 

2010

  • J. Dahle, K. Melhus, C. Mollatt, O. Bruland, R. Larsen
    Targeting of Non-Hodgkin lymphoma with 177Lu-HH1: Reevaluation of CD37 as target for radioimmunotherapy. Poster at European Association of Nuclear Medicine Annual Meeting 2010 in Vienna, Austria.
    Download PDF